Weekly Analysts’ Ratings Updates for LivaNova (LIVN)

A number of firms have modified their ratings and price targets on shares of LivaNova (NASDAQ: LIVN) recently:

• 2/26/2025 – LivaNova was downgraded by analysts at Wolfe Research from an “outperform” rating to a “peer perform” rating.
• 2/26/2025 – LivaNova had its price target lowered by analysts at Mizuho from $70.00 to $60.00. They now have an “outperform” rating on the stock.
• 2/26/2025 – LivaNova was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 2/26/2025 – LivaNova had its price target lowered by analysts at Stifel Nicolaus from $72.00 to $60.00. They now have a “buy” rating on the stock.
• 2/26/2025 – LivaNova had its price target lowered by analysts at Needham & Company LLC from $75.00 to $64.00. They now have a “buy” rating on the stock.
• 2/14/2025 – LivaNova was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 1/28/2025 – LivaNova had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $75.00 price target on the stock.
• 1/23/2025 – LivaNova was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 1/15/2025 – LivaNova was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.

LivaNova Stock Performance

NASDAQ:LIVN opened at $41.45 on Thursday. The firm’s fifty day simple moving average is $47.65 and its 200 day simple moving average is $49.56. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a twelve month low of $40.37 and a twelve month high of $64.47. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of 98.69 and a beta of 1.00.

Insider Buying and Selling at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares of the company’s stock, valued at $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.27% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On LivaNova

Large investors have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue lifted its holdings in LivaNova by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after buying an additional 425 shares in the last quarter. abrdn plc lifted its stake in shares of LivaNova by 43.8% in the third quarter. abrdn plc now owns 232,025 shares of the company’s stock worth $12,191,000 after acquiring an additional 70,618 shares in the last quarter. Emerald Advisers LLC boosted its holdings in LivaNova by 2.1% in the third quarter. Emerald Advisers LLC now owns 695,505 shares of the company’s stock valued at $36,542,000 after purchasing an additional 14,302 shares during the last quarter. Atria Investments Inc grew its stake in LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after purchasing an additional 331 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D increased its holdings in LivaNova by 38.3% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 42,539 shares of the company’s stock worth $2,235,000 after purchasing an additional 11,782 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.